A focused collection of 29 calculators, scores, and clinical references.
ADA 10-Year Cardiovascular Risk Model: Explanation and Clinical Context This model estimates the 10-year risk of atherosclerotic cardiovascular disease (ASCVD) based on factors such as age, gender, race, cholesterol levels, blood pressure, diabetes status, and smoking history. It is derived from the Pooled Cohort Equations, which are widely used for cardiovascular risk assessment.
Advanced CVD Risk Model: Explanation and Clinical Context The Advanced CVD Risk Model, developed by the American Heart Association, estimates the 10-year risk of cardiovascular events in individuals aged 30–79 years without a history of cardiovascular disease. This model incorporates factors such as age, sex, race, smoking status, diabetes, systolic blood pressure, total cholesterol, and HDL cholesterol levels to pro
ApoB/ApoA1 Ratio: Explanation and Clinical Context The ApoB/ApoA1 ratio is a validated biomarker reflecting the balance between atherogenic and anti-atherogenic lipoproteins. ApoB represents the total number of atherogenic particles (including LDL, VLDL), while ApoA1 is the main protein in HDL, which is protective. A higher ApoB/ApoA1 ratio indicates a predominance of atherogenic lipoproteins and a higher risk for ca
ARIC Diabetes CVD Score: Explanation and Clinical Context The ARIC Diabetes CVD Score is a validated risk assessment tool to estimate the 10-year risk of cardiovascular disease in adults with type 2 diabetes. It was derived from the Atherosclerosis Risk in Communities (ARIC) study cohort and incorporates patient-specific variables including age, sex, systolic blood pressure, total cholesterol, HDL cholesterol, smokin
ASCVD-DM Subscore: Explanation and Clinical Context The ASCVD-DM Subscore is a clinical tool designed to estimate the 10-year risk of atherosclerotic cardiovascular disease (ASCVD) specifically in patients with type 2 diabetes mellitus. It incorporates traditional ASCVD risk factors such as age, sex, total cholesterol, HDL cholesterol, systolic blood pressure, antihypertensive treatment, smoking status, and diabetes
Atherogenic Index of Plasma (AIP): Explanation and Clinical Context The Atherogenic Index of Plasma (AIP) is calculated as the base-10 logarithm of the ratio of plasma triglycerides (TG) to high-density lipoprotein cholesterol (HDL-C) in mmol/L: log10(TG/HDL-C). It serves as a sensitive marker of plasma atherogenicity and is closely associated with the size of LDL particles, with higher AIP indicating a predominance
Bioimpedance Scale Body Fat Explanation and Clinical Context Bioimpedance scales estimate body fat percentage by analyzing the resistance of body tissues to a low level electrical current. Lean tissue contains more water and conducts electricity more easily, whereas fat tissue provides higher resistance. Consumer bioimpedance devices combine anthropometric variables such as height, weight, age, and sex to improve est
BMI Based Body Fat Percentage Explanation and Clinical Context BMI based body fat estimation uses body mass index, age, and sex to approximate total body fat percentage. This method is derived from population based regression models and provides a simple alternative when direct body composition measurement is unavailable. Body mass index reflects the relationship between body weight and height but does not differenti
Body Mass Index: Explanation and Clinical Context Body Mass Index is a commonly used anthropometric measure that relates weight to height and provides a general estimation of body fatness. BMI is calculated by dividing weight in kilograms by the square of height in meters. Although BMI does not directly measure adiposity, it is widely adopted because of its simplicity, reproducibility, and strong correlation with var
: Explanation and Clinical Context Body surface area represents the external surface area of the human body and is widely used in clinical medicine because it correlates more closely with physiological parameters compared to actual body weight. BSA is routinely applied in cardiovascular care, nephrology, oncology, and critical care medicine. In hemodynamics, BSA is essential for calculating cardiac index, which is th
DIAL2 Score: Explanation and Clinical Context The DIAL2 (Diabetes Lifespan) model estimates the lifetime risk of cardiovascular disease (CVD) and CVD-free life expectancy in individuals with type 2 diabetes without prior CVD history. Developed using data from the Swedish National Diabetes Register, the model incorporates factors such as age, sex, smoking status, BMI, HbA1c, systolic blood pressure, and LDL cholestero
Epicardial Fat Thickness Index (EFTI): Explanation and Clinical Context Epicardial fat is the visceral fat depot surrounding the myocardium and coronary arteries. Measuring its thickness using echocardiography provides an estimate of cardiac visceral adiposity. The Epicardial Fat Thickness Index (EFTI) normalizes epicardial fat thickness to body surface area (BSA), allowing more accurate inter-patient comparisons. In
FIB-4 Score (for NAFLD-related CV risk): Explanation and Clinical Context The FIB-4 score is a non-invasive scoring system used to estimate liver fibrosis, particularly in patients with NAFLD. It is calculated using age, AST, ALT, and platelet count. It helps identify patients at low, intermediate, or high risk of advanced liver fibrosis, which has implications for cardiovascular risk stratification, as advanced fibr
Framingham BMI Model: Explanation and Clinical Context The Framingham BMI Model estimates the 10-year risk of developing cardiovascular disease (CVD) using readily available clinical parameters including age, sex, systolic blood pressure, total cholesterol, HDL cholesterol, smoking status, and BMI. Unlike lipid-based models, BMI is used as a substitute for direct lipid measurements in some versions. The model calcula
HOMA-IR (Homeostatic Model Assessment of Insulin Resistance): Explanation and Clinical Context HOMA-IR is a validated index used to estimate insulin resistance based on fasting plasma glucose and insulin levels. The formula is: HOMA-IR = (Fasting Glucose [mg/dL] × Fasting Insulin [µU/mL]) / 405. Higher HOMA-IR values indicate greater insulin resistance. It is commonly used in metabolic and cardiometabolic research an
hs-CRP Tertile Risk Category: Explanation and Clinical Context The hs-CRP (high-sensitivity C-reactive protein) tertile risk categorization stratifies patients into low, intermediate, or high risk of future cardiovascular events based on their hs-CRP levels. According to Ridker et al. (Circulation, 2000), the 1st tertile (<1.0 mg/L) represents low risk, the 2nd tertile (1.0–3.0 mg/L) represents intermediate risk, and
Hypertriglyceridemic Waist (HTGW) Index: Explanation and Clinical Context The HTGW Index is a simple clinical tool combining waist circumference and fasting triglyceride levels to identify individuals at increased cardiometabolic risk. It was first described by Lemieux et al. in 2007 as a marker for visceral obesity and associated metabolic abnormalities, such as insulin resistance, atherogenic dyslipidemia, and incr
INSPIRE Index (Insulin Sensitivity Prognosis): Explanation and Clinical Context The INSPIRE Index is a prognostic tool used to estimate insulin sensitivity and risk of progression to metabolic and cardiovascular complications. It is calculated using fasting plasma glucose and fasting insulin, based on the HOMA-IR model. A lower INSPIRE Index indicates higher insulin sensitivity and lower cardiometabolic risk, whereas
Integrated Discrimination Improvement (IDI): Explanation and Clinical Context Integrated Discrimination Improvement (IDI) is a metric used to evaluate the improvement in risk prediction offered by a new model compared with a baseline model. It quantifies the change in predicted probabilities for events and non-events, measuring how much better a new model separates patients who experience an event from those who do n
Lipid Accumulation Product (LAP): Explanation and Clinical Context LAP is an index that quantifies lipid overaccumulation based on waist circumference and fasting triglyceride levels. It is designed to identify individuals with excess visceral fat and elevated cardiometabolic risk. The formula differs by sex: for men, LAP = (waist circumference [cm] - 65) × triglycerides [mmol/L]; for women, LAP = (waist circumferenc
Metabolic Syndrome Severity Z-Score: Explanation and Clinical Context The Metabolic Syndrome Severity Z-Score is a continuous measure of metabolic syndrome severity derived from waist circumference, blood pressure, fasting glucose, triglycerides, and HDL cholesterol, adjusted for age and sex. This score allows clinicians and researchers to quantify metabolic risk on a continuous scale rather than a binary presence/ab
MONICA Risk Score (Metabolic Syndrome Outcomes): Explanation and Clinical Context The MONICA Risk Score was developed as part of the WHO MONICA Project to estimate the 10-year risk of cardiovascular events, particularly in individuals with features of metabolic syndrome. It combines age, systolic blood pressure, total cholesterol, HDL cholesterol, fasting glucose, and smoking status into a point-based scoring system.
NAFLD Fibrosis Score (NFS): Explanation and Clinical Context The NAFLD Fibrosis Score is a non-invasive scoring system designed to estimate the likelihood of advanced fibrosis in patients with non-alcoholic fatty liver disease (NAFLD). It incorporates readily available clinical parameters including age, BMI, impaired fasting glucose/diabetes, AST/ALT ratio, platelet count, and albumin level. The resulting score strat
Navy Method Body Fat Explanation and Clinical Context The Navy Method is an anthropometric formula used to estimate body fat percentage based on body circumference measurements. It requires height, waist circumference, and neck circumference for men, with additional hip circumference for women. This method was developed by the United States Navy as a practical field tool that does not require advanced equipment. Norm
Net Reclassification Index (NRI): Explanation and Clinical Context The Net Reclassification Index (NRI) is a statistical metric used to quantify the improvement in risk prediction offered by a new model compared to an existing model. It evaluates whether individuals with events (cases) are more correctly reclassified into higher risk categories and whether individuals without events (non-cases) are correctly reclassi
QDiabetes Risk Algorithm: Explanation and Clinical Context QDiabetes is a validated risk prediction tool designed to estimate the 10-year risk of developing type 2 diabetes in adults. It uses demographic and clinical variables readily available in primary care, including age, sex, BMI, family history of diabetes, smoking status, ethnicity, and deprivation score. The algorithm applies a logistic regression model to co
TG/HDL-C Ratio: Explanation and Clinical Context The triglyceride to HDL-cholesterol (TG/HDL-C) ratio is a simple, reliable marker used to estimate insulin resistance and cardiometabolic risk. It is calculated by dividing fasting triglycerides (mg/dL) by HDL-C (mg/dL). A low ratio (<2) generally indicates low risk for insulin resistance and cardiovascular events, while a high ratio (>4) suggests significant insulin r
UKPDS Risk based cardiac risk calculator: clinical explanation and context The UKPDS risk approach was developed from a large prospective cohort of people with type two diabetes followed during the United Kingdom Prospective Diabetes Study. The model incorporates age, sex, duration of diabetes, glycemic control, systolic blood pressure, lipid measures, smoking status, and markers of renal involvement to estimate the
Visceral Adiposity Index (VAI): Explanation and Clinical Context Visceral Adiposity Index (VAI) is a gender-specific mathematical model that estimates visceral fat function and distribution using simple anthropometric and metabolic parameters: BMI, waist circumference, triglycerides, and HDL-cholesterol. VAI correlates with cardiometabolic risk and insulin sensitivity, providing a surrogate marker for visceral obesit